MX367370B - Compuestos. - Google Patents
Compuestos.Info
- Publication number
- MX367370B MX367370B MX2016009893A MX2016009893A MX367370B MX 367370 B MX367370 B MX 367370B MX 2016009893 A MX2016009893 A MX 2016009893A MX 2016009893 A MX2016009893 A MX 2016009893A MX 367370 B MX367370 B MX 367370B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- kinase activity
- lrrk2 kinase
- compounds
- als
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
La presente invención se refiere a compuestos novedosos que inhiben la actividad de las cinasas LRRK2, procesos para su preparación, composiciones que las contienen y su uso en el tratamiento o la prevención de enfermedades caracterizadas por la actividad de las cinasas LRRK2, por ejemplo, la enfermedad de Parkinson, la enfermedad de Alzheimer y la esclerosis lateral amiotrófica (ELA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014000139 | 2014-01-29 | ||
PCT/CN2015/000055 WO2015113452A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016009893A MX2016009893A (es) | 2016-10-31 |
MX367370B true MX367370B (es) | 2019-08-16 |
Family
ID=53756224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009893A MX367370B (es) | 2014-01-29 | 2015-01-28 | Compuestos. |
Country Status (20)
Country | Link |
---|---|
US (2) | US10087186B2 (es) |
EP (1) | EP3099695B1 (es) |
JP (1) | JP6422986B2 (es) |
KR (1) | KR20160106622A (es) |
CN (1) | CN105940004B (es) |
AU (2) | AU2015210593A1 (es) |
CA (1) | CA2937431A1 (es) |
CL (1) | CL2016001895A1 (es) |
CR (1) | CR20160348A (es) |
DO (2) | DOP2016000195A (es) |
EA (1) | EA029774B1 (es) |
ES (1) | ES2802174T3 (es) |
IL (1) | IL246579B (es) |
MA (1) | MA39219B1 (es) |
MX (1) | MX367370B (es) |
PE (1) | PE20161443A1 (es) |
PH (1) | PH12016501307A1 (es) |
SG (1) | SG11201605342UA (es) |
UA (1) | UA118369C2 (es) |
WO (1) | WO2015113452A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
ES2802174T3 (es) | 2014-01-29 | 2021-01-15 | Glaxosmithkline Ip Dev Ltd | Compuestos |
RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼlrrk2阻害剤としての使用、及びその調製方法 |
CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
RS62868B1 (sr) | 2016-06-16 | 2022-02-28 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za upotrebu u lečenju neurodegenerativnih poremećaja |
CN110446700A (zh) * | 2017-01-25 | 2019-11-12 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE |
KR101896568B1 (ko) * | 2017-03-23 | 2018-09-10 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
SG11202005264PA (en) | 2017-12-05 | 2020-07-29 | Oscotec Inc | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
MX2021003516A (es) | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals Llc | Compuesto de aminopirimidina. |
CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
CN114426542B (zh) * | 2020-10-29 | 2023-06-30 | 苏州亚宝药物研发有限公司 | 取代的二芳基胺化合物及其药物组合物、制备方法和用途 |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
WO2024056775A1 (en) | 2022-09-15 | 2024-03-21 | H. Lundbeck A/S | Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070542A1 (en) | 2003-09-03 | 2005-03-31 | Hodgetts Kevin J. | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
DK1802749T3 (da) | 2004-10-21 | 2012-11-26 | Mayo Foundation | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
AU2006301435A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as Syk inhibitors |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20090325964A1 (en) | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
IN2012DN02763A (es) * | 2009-09-29 | 2015-09-18 | Glaxo Group Ltd | |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
RS59106B1 (sr) * | 2010-11-10 | 2019-09-30 | Genentech Inc | Derivati pirazol aminopirimidina kao lrrk2 modulatori |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ1デルタ(ck1デルタ)阻害剤 |
CN103492389B (zh) * | 2011-04-21 | 2016-09-14 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
SG2014014450A (en) | 2011-09-22 | 2014-09-26 | Pfizer | Pyrrolopyrimidine and purine derivatives |
KR101996699B1 (ko) * | 2011-11-30 | 2019-07-04 | 제넨테크, 인크. | Lrrk2에 대해 양전자 방사 단층촬영(pet) 이미징을 위한 불소-18 및 탄소-11 표지된 방사선 리간드 |
GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
MX363118B (es) | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
CN106279202A (zh) | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン |
ES2802174T3 (es) | 2014-01-29 | 2021-01-15 | Glaxosmithkline Ip Dev Ltd | Compuestos |
RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
-
2015
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Application Discontinuation
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en active Application Filing
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en active Active
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501307B1 (en) | Compounds | |
PH12017501921A1 (en) | Novel compounds | |
BR112018001303A2 (pt) | ?compostos? | |
PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
SA518391170B1 (ar) | مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
UY37808A (es) | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 | |
WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MX368781B (es) | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. | |
SG179120A1 (en) | Novel compounds | |
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
MX2017003470A (es) | Inhibidores macrociclicos de cinasa lrrk2. | |
UY37580A (es) | Compuestos novedosos que inhiben la actividad de cinasa lrrk2 | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
GB2553686A8 (en) | Ethynylxanthines, preparation and use as calcium ion channel modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |